Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2014-04-21 | Jason M. Aryeh(N) Director 2006 45 ... The nominating and corporate governance committee currently consists of Mr. Aryeh (chair) and Drs. Kozarich and Sabba. ... The compensation committee consists of Messrs. Aryeh, Davis (chair) and Knott and Dr. LaMattina. ... Jason M. Aryeh(1) 59,000 94,478 149,647 — 303,125 ... (1) As of December 31, 2013, Mr. Aryeh held options to purchase 30,968 shares of our common stock and 2,925 unvested shares of restricted stock. During 2013, Mr. Aryeh received 2,925 restricted stock units with a grant date fair value of $94,478 and 7,335 stock options with a grant date fair value of $149,647. Mr. Aryeh elected to receive his retainer in cash. |
| 2015-03-13 | Jason M. Aryeh(C)(N) - Director, Age 46, Member of the compensation committee (C) and nominating and corporate governance committee (N). Compensation: $280,159 in 2014. |
| 2016-04-12 | Jason M. Aryeh(C)(N) Director 47 2006 (C) Member of the compensation committee (N) Member of the nominating and corporate governance committee ... Compensation of Directors ... Jason M. Aryeh(1) As of December 31, 2015, Mr. Aryeh held options to purchase 9,399 shares of our common stock and 925 restricted stock units. During 2015, Mr. Aryeh received 925 restricted stock units with a grant date fair value of $83,019 and 2,754 stock options with a grant date fair value of $139,946. ... Cash Fees $62,564 Stock Awards $83,019 Option Awards $139,946 Total $285,529 |
| 2017-04-14 | Jason M. Aryeh(C)(N) Director 2006 48 ... The nominating and corporate governance committee currently consists of Mr. Aryeh (chair) and Drs. Kozarich and Sabba. ... The compensation committee consists of Messrs. Aryeh and Davis (chair) and Dr. LaMattina. ... Jason M. Aryeh 64,724 74,205 140,557 279,486 ... During 2016, Mr. Aryeh received 622 restricted stock units with a grant date fair value of $74,205 and 2,329 stock options with a grant date fair value of $140,557. |
| 2018-04-30 | Jason M. Aryeh(C)(N) Director 2006 49; Member of the compensation committee and nominating and corporate governance committee; 2017 compensation total $277,156. |
| 2019-04-24 | Jason M. Aryeh (C)(N) 50 2006 Founder and Managing General Partner of JALAA Equities, LP ... Mr. Aryeh received 493 restricted stock units with a grant date fair value of $96,584 and 2,474 stock options with a grant date fair value of $186,596. Total: $345,865. |
| 2020-04-24 | Jason M. Aryeh (C)(N) 51 2006 Founder and Managing General Partner of JALAA Equities, LP ... Mr. Aryeh’s experience in capital markets, including his service as managing general partner of a hedge fund focused on the life sciences sector, contributed to our board of directors’ conclusion that he should serve as a director of our company. ... The nominating and corporate governance committee currently consists of Mr. Aryeh (chair) and Drs. Kozarich and Sabba. ... The compensation committee consists of Messrs. Aryeh and Davis (chair) and Dr. LaMattina. ... The following table provides information related to the compensation of each of our non-employee directors for fiscal 2019. ... Jason M. Aryeh 67,527 94,848 190,025 352,400 ... (1) As of December 31, 2019, Mr. Aryeh held options to purchase 17,396 shares of our common stock and 835 restricted stock units. During 2019, Mr. Aryeh received 835 restricted stock units with a grant date fair value of $94,848 and 4,071 stock options with a grant date fair value of $190,025. |
| 2020-11-12 | The following table provides information related to the compensation of each of our non-employee directors for fiscal 2019. Jason M. Aryeh Cash Fees $67,527, Stock Awards $94,848, Option Awards $190,025, Total $352,400 |
| 2021-04-23 | Jason M. Aryeh has served as a member of our board of directors since September 2006. Mr. Aryeh has more than twenty years of equity investment experience focused on the life sciences industry. He is the Founder and Managing General Partner of JALAA Equities, LP, a private investment fund focused on the biotechnology and medical device sectors. He has served in such capacity since 1997. Mr. Aryeh currently serves on the board of directors of Orchestra BioMed and Anebulo Pharmaceuticals. Since 2006, Mr. Aryeh has served as chairman of the board, on the board of directors or as a consultant to many public and private life sciences companies and charitable foundations, including the Cystic Fibrosis Foundation’s Therapeutics Board. Mr. Aryeh also serves as chairman of the board of directors of Rio Grande Renewables, LLC, a renewable energy company he co-founded in 2009. Mr. Aryeh earned a B.A. in economics, with honors, from Colgate University, and is a member of the Omnicron Delta Epsilon Honor Society in economics. Mr. Aryeh’s experience in capital markets, including his service as managing general partner of a hedge fund focused on the life sciences sector, contributed to our board of directors’ conclusion that he should serve as a director of our company. |
| 2022-04-22 | Jason M. Aryeh has served as a member of our board of directors since September 2006. Mr. Aryeh has more than twenty years of equity investment experience focused on the life sciences industry. He is the Founder and Managing General Partner of JALAA Equities, LP, a private investment fund focused on the biotechnology and medical device sectors. Mr. Aryeh also serves as chairman of the board of directors of Rio Grande Renewables, LLC, a renewable energy company he co-founded in 2009. Mr. Aryeh’s experience in capital markets, including his service as managing general partner of a hedge fund focused on the life sciences sector, contributed to our board of directors’ conclusion that he should serve as a director of our company. He is a member of the human capital management and compensation committee and the nominating and corporate governance committee. Total compensation for 2021 was $322,807. |
| 2023-04-20 | Jason M. Aryeh has served as a member of the Board since September 2006. Mr. Aryeh has more than twenty years of equity investment experience focused on the life sciences industry. He is the Founder and Managing General Partner of JALAA Equities, LP, a private investment fund focused on the biotechnology and medical device sectors. He has served in such capacity since 1997. Mr. Aryeh currently serves on the board of directors of Anebulo Pharmaceuticals, a publicly-traded biotechnology company as well as on the board of directors of Orchestra BioMed, a privately-held life sciences company. Since 2006, Mr. Aryeh has served as chairman of the board, on the board of directors or as a consultant to many other public and private life sciences companies and charitable foundations, including the Novelion Therapeutics Inc. board from June 2012 to August 2018 and the Cystic Fibrosis Foundation’s Therapeutics board. Mr. Aryeh also serves as chairman of the board of directors of Rio Grande Renewables, LLC, a renewable energy company he co-founded in 2009. Mr. Aryeh earned a B.A. in economics, with honors, from Colgate University, and is a member of the Omnicron Delta Epsilon Honor Society in economics. Mr. Aryeh’s experience in capital markets, including his service as managing general partner of a hedge fund focused on the life sciences sector, contributed to the Board’ conclusion that he should serve as a director of our company. |
| 2024-04-25 | Jason M. Aryeh (HC)(N) 55 2006 Founder and Managing General Partner of JALAA Equities, LP ... (A) Member of the audit committee (the “Audit Committee”). (HC) Member of the human capital management and compensation committee (the “Human Capital Management and Compensation Committee”). (N) Member of the nominating and corporate governance committee (the “Nominating and Corporate Governance Committee”). ... DIRECTOR COMPENSATION TABLE ... Jason M. Aryeh $67,596 $84,234 $187,371 $339,201 ... The Audit Committee currently consists of Dr. Gray, Mr. Haas and Dr. Sabba (Chair). The Nominating and Corporate Governance Committee currently consists of Mr. Aryeh (Chair), Ms. Zimmermann and Drs. Gray and Kozarich. The Human Capital Management and Compensation Committee consists of Mr. Aryeh, Mr. Haas (Chair) and Dr. LaMattina. |
| Filing Date | Source Excerpt |
|---|---|
| 2009-04-22 | Jason M. Aryeh, age 40, has been a director of the Company since 2006. He is the founder and general partner of JALAA Equities, LP, a private hedge fund formed in 1996 with a focus on biotechnology and specialty pharmaceutical companies. Mr. Aryeh also serves on the board of directors of Ligand Pharmaceuticals. The Nominating and Governance Committee currently consists of Messrs. Aryeh and Harvey, Ms. Jenckes and Mr. Sudovar (Chairman). The following table sets forth compensation actually paid, earned or accrued during fiscal year 2008 by the Companys directors. Jason Aryeh Fees Earned or Paid in Cash $52,000, Option Awards $52,200, Total $104,200. |
| 2010-04-16 | Jason M. Aryeh, age 41, has been a director of the Company since 2006. ... Mr. Aryeh's experience in the biotechnology industry ... were among the factors considered by the Board of Directors in determining that Mr. Aryeh should be nominated for election as a director. ... The Nominating and Governance Committee currently consists of Messrs. Aryeh and Harvey, Ms. Jenckes and Mr. Sudovar (Chairman). ... The following table sets forth compensation actually paid, earned or accrued during fiscal year 2009 by the Company's directors. Jason Aryeh Fees Earned or Paid in Cash 40,500 Option Awards 40,543 All Other Compensation 12,656 Total 93,699 |
| 2011-04-20 | Jason M. Aryeh, age 42, has been a director of the Company since 2006. ... Mr. Aryeh's experience in the biotechnology industry... The Compensation Committee currently consists of Messrs. Harvey (Chairman), Aryeh and Cox... The following table sets forth compensation actually paid, earned or accrued during fiscal year 2010 by the Company's directors. Jason Aryeh 33,500 Fees Earned or Paid in Cash, 68,044 Option Awards, 101,544 Total. |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-22